Table 1A. Clinical characteristics for LNM patients with or without one or two bone metastase.
| Timing for characteristics | Clinical characteristics and treatments | All patients (n = 45) | Patients with LNM (n = 35) | Patients with LNM and one or two bone metastases (n = 10) |
|---|---|---|---|---|
| Findings at diagnosis | Age (years, median, IQR) | 61 (57–66) | 62 (58–69) | 60 (51–64) |
| Gleason score 6 | 1 | 1 | 0 | |
| Gleason score 7 | 17 | 12 | 5 | |
| Gleason score 8 | 11 | 10 | 1 | |
| Gleason score 9 | 7 | 4 | 3 | |
| LNM | 13 | 10 | 3 | |
| Initial treatment | RP | 29 | 20 | 9 |
| RP with pelvic lymph node dissection | 13 | 9 | 4 | |
| Radiotherapy | 13 | 13 | 0 | |
| Adjuvant treatment | Radiotherapy | 13 | 13 | 0 |
| Adjuvant or neoadjuvant ADT | 10 | 8 | 2 | |
| Number of salvage treatments before LuPRLT (median, range) | 2 (1–4) | 2 (1–4) | 3.5 (3–4) | |
| Radiotherapy | 10 | 4 | 6 | |
| Lymph node dissection | 3 | 2 | 1 | |
| ADT | 14 | 8 | 6 | |
| Docetaxel | 12 | 7 | 5 | |
| Abiraterone | 10 | 7 | 3 | |
| Enzalutamide | 3 | 1 | 2 | |
| Findings at start of LuPRLT | Age (years, median, IQR) | 70 (64–75) | 72 (65–75) | 68 (63–72) |
| PSA (µg/l, median, IQR) | 18.2 (3.3–39) | 18.2 (2.3–39) | 19.3 (4.1–49) |
Abbreviations: ADT, androgen deprivation therapy; IQR, interquartile range; LNM, lymph node metastases; LuPRLT, 177Lu-prostate-specific membrane antigen radioligand therapy; RP, radical prostatectomy.